Sales training for REAL behaviour change
New Pharm Exec Europe supplement explores how sales reps' thinking and behaviour can really be changed.
The articles by IMS's Kevin Dolgin in Pharm Exec Europe'slatest supplement are very much concerned with the best kind of training that is, training that works, and achieves the desired goal of affecting a real behavioural change in the sales force. Kevin investigates the methodologies that lie behind successful training programmes, and, importantly, also looks beyond the methodologies to the management support that is necessary to sustain the lessons learned and to facilitate the new practices. And, as he perceptively observes, the power of conforming to peer group behaviour should not be underestimated: the more we start to think and do things differently after training, the more our colleagues will follow.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
